Sunday, June 20, 2021 8:00:49 PM
Now NR2F6 is proving to be a significant receptor in most cancers. Proven. Peer reviewed studies. Google.
The mRNA science is now just unfolding in fashion it should have been for 2 decades. Especially with lab space and funding! And anyone early, before now, with significant protections, is about to be paid and or funded. Like Regen has already started(need to get current for the real work to start IMHO) and its just begun!! Our History of connections and collaboration is undeniable. Thousands of lab hours. Undeniable. All add to the value of one thing. Our IP.
Dr David Koos and the NR2F6 IP with Regen is cutting edge. It secured the most significant aspects of an entire receptor, proving to be more significant of a receptor then any other with cancer.
The funding ran out for Dr Koos, some folks got mad. Even tho again, mRNA/siRNA was considered abstract even up to 9 months ago! In History!
Think any new funding around in Biotech for front running mRNA protections and license/royalties exposure?
Now think about the specific shares Dr Koos added to the articles of incorporation of Regen.
Wake up. Quickly.
Sometimes its Skil, Sometimes its Luc.
I Appreciate All Member Follows!
Desperate Sellers Become Desperate Buyers. Vice Versa
ALL IMHO.
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM